Iambic Therapeutics Filed IND for Novel Cancer Drug
The San Diego biotech aims to initiate human trials for its AI-designed brain-penetrant KIF18A inhibitor.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Will AI-driven platforms significantly shorten the development time for new cancer medications?
San Diego-based Iambic Therapeutics has submitted an Investigational New Drug application to the FDA for IAM217. This compound is a brain-penetrant inhibitor designed to treat solid tumors with chromosomal instability, such as triple-negative breast cancer and ovarian cancer.
Why it matters
The development marks a milestone in using AI to accelerate drug discovery, with Iambic identifying lead compounds in approximately six months. By targeting KIF18A, a mitotic motor protein, the drug aims to disrupt cell division in cancers that rely on chromosomal instability for survival.
IAM217 achieved 90% regression of intracranial tumors in preclinical models and reached 10 nM potency in optimized compounds. The design process utilized the NeuralPLexer tool for structural insights and Enchant AI tools for multi-parameter optimization.
The players
Iambic Therapeutics
A San Diego-based biotechnology company that utilizes AI-driven platforms to design and optimize small-molecule drug candidates.
FDA
The United States federal agency responsible for regulating new drug applications and clinical trial oversight.
The details
IAM217 functions as an inhibitor of KIF18A, a mitotic motor protein—a protein that acts as a molecular motor to move components during cell division. Cancer cells with chromosomal instability, where cells have an abnormal number of chromosomes, rely on this protein to complete division successfully. Iambic used its AI-driven platform, incorporating NeuralPLexer to model protein structures and Enchant to predict compound properties, to design the inhibitor for brain penetrance.
Timeline
October 5, 2026: Iambic submitted the IND for IAM217 to the FDA.
Q4 2026: Iambic anticipates submitting an IND for its IAM-C1 candidate.
The Tech Race
This submission follows the established trajectory of the company's platform, which previously advanced IAM1363 to clinical trials in two years. It places the firm among the cohort of biotech startups competing to shrink the time-to-clinic for small-molecule oncology candidates.
IAM217 is currently in the research and regulatory submission stage and is not available for patient treatment. The timeline for its entry into the clinic depends on the outcome of the FDA's current review of the submitted IND application.
The takeaway
Iambic's move highlights the shortening cycle times for AI-designed oncology drugs, moving from initial hits to regulatory submission in months rather than years. Observers should monitor for FDA feedback regarding the Phase 1/2 clinical trial initiation.
What happens next
Subject to FDA clearance, Iambic plans to initiate a Phase 1/2 clinical trial for IAM217.
Further reading
Learn more about the latest innovations in Biotech.
Live Poll
Will AI-driven platforms significantly shorten the development time for new cancer medications?
